Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Battered XenoPort Holds On For April PDUFA Date For Horizant

Executive Summary

XenoPort Inc. is even more focused on the April 6 review deadline for its lead candidate, Horizant, for restless leg syndrome, after its second-string compound came up short in a Phase IIb trial in gastroesophageal reflux disease.

You may also be interested in...



FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK

The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.

FDA Approves Horizant For Restless Legs Syndrome, Bringing Relief To XenoPort, Revenues To GSK

The California biotech likely to get a lifeline, while GSK will benefit from incremental revenues, but the market, including payers, has to yet to be educated.

XenoPort Gives Up On Reflux Drug After It Fails To Beat Placebo

Negative results thwart a potential partnership strategy surrounding arbaclofen placerbil, which still holds potential in spasticity.

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel